RomiDEPsin - Clinical Trials

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

Who is this study for: Patients with relapsed or refractory peripheral T-cell lymphoma

Enrollment Status: Recruiting

Publish Date: January 21, 2026

Intervention Type: Drug

Study Drugs: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine

Study Phase: Phase 2

Summary: The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidine to single agent drugs already determined effective in patients with PTCL. For the purposes of this study, the single a...

HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer

Enrollment Status: Recruiting

Publish Date: December 03, 2025

Intervention Type: Drug

Study Phase: Phase 1

Summary: In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

Who is this study for: Adult patients with Peripheral T Cell Lymphoma

Enrollment Status: Recruiting

Publish Date: March 31, 2022

Intervention Type: Drug

Study Drugs: Durvalumab, Pralatrexate, Romidepsin, Azacitidine

Study Phase: Phase 1/Phase 2

Summary: This is an open-label, Phase 1/2a, dose-finding study with an initial phase 1 portion, articulated in four separate treatment arms, followed by a dedicated phase 2 for qualifying treatment Arm(s). The primary objective of the Phase 1 portion is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of: Durvalumab, oral 5-azacitidine, and romidepsin (Arm ...